Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

89bio, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 ENLIGHTEN-FIBROSIS AND ENLIGHTEN-CIRRHOSIS PHASE 3 TOPLINE HISTOLOGY DATA EXPECTED IN 1H 2027 AND IN 2028, RESPECTIVELY; EACH TRIAL DESIGNED TO SUPPORT ACCELERATED APPROVAL TO TREAT PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)   ENTRUST PHASE 3 TOPLINE DATA IN SEVERE HYPERTRIGLYCERIDEMIA (SHTG) EXPECTED IN 1Q 2026   CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES TOTALED $561.2 MILLION AS OF JUNE 30, 2025  SAN FRANCISCO, AUG. 07, 2025 (GLOBE NEWSWIRE) -- 89BIO, INC. (NASDAQ: ETNB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE THERAPIES FOR THE TREATMENT OF LIVER AND CARDIOMETABOLIC DISEASES, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED CORPORATE UPDATES. AS WE ENTER THE SECOND HALF OF 2025, WE REMAIN DILIGENTLY FOCUSED ON EXECUTION ACROSS OUR THREE GLOBAL PHASE 3 TRIALS FOR PEGOZAFERMIN IN MASH AND SHTG.

89BIO REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND CORPORATE UPDATES

SAN FRANCISCO, AUG. 04, 2025 (GLOBE NEWSWIRE) -- 89BIO, INC. (THE COMPANY OR 89BIO) (NASDAQ: ETNB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE THERAPIES FOR THE TREATMENT OF LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS APPROVED THE GRANT OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 267,000 SHARES OF THE COMPANY'S COMMON STOCK TO THREE NEW EMPLOYEES (THE INDUCEMENT GRANTS) ON AUGUST 1, 2025 (THE GRANT DATE). THE INDUCEMENT GRANTS HAVE BEEN GRANTED PURSUANT TO THE COMPANY'S 2023 INDUCEMENT PLAN (THE PLAN). THE INDUCEMENT GRANTS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THESE INDIVIDUALS ENTERING INTO EMPLOYMENT WITH 89BIO IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

89BIO ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

SAN FRANCISCO, JULY 09, 2025 (GLOBE NEWSWIRE) -- 89BIO, INC. (THE COMPANY OR 89BIO) (NASDAQ: ETNB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE THERAPIES FOR THE TREATMENT OF LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS APPROVED THE GRANT OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 32,350 SHARES OF THE COMPANY'S COMMON STOCK TO TWO NEW EMPLOYEES (THE INDUCEMENT GRANTS) ON JULY 2, 2025 (THE GRANT DATE). THE INDUCEMENT GRANTS HAVE BEEN GRANTED PURSUANT TO THE COMPANY'S 2023 INDUCEMENT PLAN (THE PLAN). THE INDUCEMENT GRANTS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THESE INDIVIDUALS ENTERING INTO EMPLOYMENT WITH 89BIO IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

SAN FRANCISCO, JUNE 06, 2025 (GLOBE NEWSWIRE) -- 89BIO, INC. (THE COMPANY OR 89BIO) (NASDAQ: ETNB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE THERAPIES FOR THE TREATMENT OF LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS APPROVED THE GRANT OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 61,100 SHARES OF THE COMPANY'S COMMON STOCK TO THREE NEW EMPLOYEES (THE INDUCEMENT GRANTS) ON JUNE 3, 2025 (THE GRANT DATE). THE INDUCEMENT GRANTS HAVE BEEN GRANTED PURSUANT TO THE COMPANY'S 2023 INDUCEMENT PLAN (THE PLAN). THE INDUCEMENT GRANTS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THESE INDIVIDUALS ENTERING INTO EMPLOYMENT WITH 89BIO IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

SAN FRANCISCO, JUNE 04, 2025 (GLOBE NEWSWIRE) -- 89BIO, INC. (THE COMPANY OR 89BIO) (NASDAQ: ETNB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE THERAPIES FOR THE TREATMENT OF LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, JUNE 11, 2025 AT 11:20 AM EDT AND PARTICIPATE IN ONE-ON-ONE INVESTOR MEETINGS.

89BIO TO PARTICIPATE IN GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

SAN FRANCISCO, MAY 09, 2025 (GLOBE NEWSWIRE) -- 89BIO, INC. (THE COMPANY OR 89BIO) (NASDAQ: ETNB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE THERAPIES FOR THE TREATMENT OF LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS APPROVED THE GRANT OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 183,885 SHARES OF THE COMPANY'S COMMON STOCK TO SEVEN NEW EMPLOYEES (THE INDUCEMENT GRANTS) ON MAY 6, 2025 (THE GRANT DATE). THE INDUCEMENT GRANTS HAVE BEEN GRANTED PURSUANT TO THE COMPANY'S 2023 INDUCEMENT PLAN (THE PLAN). THE INDUCEMENT GRANTS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THESE INDIVIDUALS ENTERING INTO EMPLOYMENT WITH 89BIO IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

SAN FRANCISCO, MAY 06, 2025 (GLOBE NEWSWIRE) -- 89BIO, INC. (THE COMPANY OR 89BIO) (NASDAQ: ETNB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE THERAPIES FOR THE TREATMENT OF LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES DURING THE MONTH OF MAY:

89BIO TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

 TOPLINE HISTOLOGY DATA FROM ENLIGHTEN-FIBROSIS AND ENLIGHTEN-CIRRHOSIS PHASE 3 TRIALS ARE EXPECTED IN 1H 2027 AND IN 2028, RESPECTIVELY; EACH TRIAL IS DESIGNED TO SUPPORT ACCELERATED APPROVAL TO TREAT PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)   THE PHASE 3 ENTRUST TRIAL IN SEVERE HYPERTRIGLYCERIDEMIA (SHTG) HAS BEEN FULLY ENROLLED AND TOPLINE DATA ARE EXPECTED IN 1Q 2026   CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES TOTALED $638.8 MILLION AS OF MARCH 31, 2025; COMPLETED FOLLOW-ON EQUITY OFFERING IN 1Q 2025 WITH GROSS PROCEEDS OF $287.5 MILLION  SAN FRANCISCO, MAY 01, 2025 (GLOBE NEWSWIRE) -- 89BIO, INC. (NASDAQ: ETNB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE THERAPIES FOR THE TREATMENT OF LIVER AND CARDIOMETABOLIC DISEASES, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED CORPORATE UPDATES. WE HAVE ENTERED 2025 WITH STRONG MOMENTUM, FUELED BY CONTINUED PROGRESS IN OUR TWO GLOBAL PHASE 3 TRIALS IN ADVANCED MASH.

89BIO REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND CORPORATE UPDATES

SAN FRANCISCO, MARCH 03, 2025 (GLOBE NEWSWIRE) -- 89BIO, INC. (THE COMPANY OR 89BIO) (NASDAQ: ETNB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE THERAPIES FOR THE TREATMENT OF LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE ON MONDAY, MARCH 10, 2025 AT 4:20 PM EST AND PARTICIPATE IN ONE-ON-ONE INVESTOR MEETINGS. THE WEBCAST OF THE FIRESIDE CHAT WILL BE ACCESSIBLE IN THE INVESTOR SECTION OF89BIO'S WEBSITE.

89BIO TO PARTICIPATE IN THE LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE

 ENLIGHTEN-FIBROSIS AND ENLIGHTEN-CIRRHOSIS PHASE 3 TRIALS IN PATIENTS WITH NON-CIRRHOTIC (F2-F3) AND COMPENSATED CIRRHOTIC (F4) METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) CONTINUE TO ADVANCE WITH TOPLINE HISTOLOGY DATA EXPECTED IN 1H 2027 AND 2028, RESPECTIVELY  THE PHASE 3 ENTRUST TRIAL IN SEVERE HYPERTRIGLYCERIDEMIA (SHTG) WILL BE UNBLINDED AFTER STUDY COMPLETION AT WEEK 52 VS. WEEK 26 FOLLOWING DISCUSSIONS WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA); TOPLINE DATA ARE NOW EXPECTED IN 1Q 2026   CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES TOTALED $440.0 MILLION AS OF DECEMBER 31, 2024; A FOLLOW-ON OFFERING IN THE 1Q 2025 RESULTED IN GROSS PROCEEDS OF $287.5 MILLION  SAN FRANCISCO, FEB. 27, 2025 (GLOBE NEWSWIRE) -- 89BIO, INC. (NASDAQ: ETNB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE THERAPIES FOR THE TREATMENT OF LIVER AND CARDIOMETABOLIC DISEASES, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2024, AND PROVIDED CORPORATE UPDATES.

89bio, Inc.

ETNB

Price

Financials Overview

Financial Reports

No items found.

Press Releases

89bio, Inc.

ETNB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ETNB